We have completed the first “Rare Disease Research and Development Program Based on Patient-Centered Principles” to Connect Rare and Intractable Patients with Researchers. The three-month schedule has been significantly reduced to one month. Patient participation in “Study on specific immune status of autoimmune disease” [Group Company Press Release]